Articles By Jack Cush, MD
ACR Fellow Training Subcommittee Report on Pandemic Experiences
Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training.
Read Article
RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)
Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.
Read Article
Short-Term (not Long-Term) Benefits to Intraarticular Hip Steroid Injection
A single ultrasound guided intra-articular hip corticosteroid injection can be quite effective in patients with hip osteoarthritis (OA).
Read Article
TNR Recap: What Patients Say about PsA
Watch this outstanding and informative Tuesday Nite Rheumatology, held on April 5th, 2022 which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush. PsA Panelists included: - Tena Brown - Christine Lindsay - Ashley Krivohlavek
Read Article
Dactylitis Indicates a Severe PsA Phenotype
A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis.
Read Article
PsA All the Way – Unmet Needs
Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss key advances and modern disease management. We're featuring guest bloggers, hosting Tuesday Night Rheumatology, posting slides and videos, and much more dedicated to PsA.
Read Article
Increased Cancer Risk with Autoimmune Disorders
The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
Read Article
The Effect of Socioeconomic Status on Lupus Outcomes
Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.
Read Article
Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis
Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.
Read Article
Baricitinib Efficacy in Alopecia Areata
The NEJM has published the results of the BRAVE-AA1 and BRAVE-AA2 trials, demonstrating that baricitinib is effective at regrowing hair in alopecia areata (AA) patients, thus paving the way for future regulatory approval for this difficult to treat disorder.
Read Article
